Reference number : GC-2017-Q1-00510, amendment number : , agreement type : G, recipient legal name : Christie, Brian (University of Victoria), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie's_x000D_
laboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate has_x000D_
prion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo from_x000D_
endogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of Lewy_x000D_
Body dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson's_x000D_
patients have this pathology). The project will involve "mapping" the expression of the pathology and activity_x000D_
of the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varying_x000D_
controlled neurological backgrounds, something routinely done in the Christie laboratory. The ability to work_x000D_
with cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in these_x000D_
cells, and if successful, the same could be carried out in rats., program purpose french : This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie's_x000D_
laboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate has_x000D_
prion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo from_x000D_
endogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of Lewy_x000D_
Body dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson's_x000D_
patients have this pathology). The project will involve "mapping" the expression of the pathology and activity_x000D_
of the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varying_x000D_
controlled neurological backgrounds, something routinely done in the Christie laboratory. The ability to work_x000D_
with cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in these_x000D_
cells, and if successful, the same could be carried out in rats., agreement title english : StressMarq biosciences - alpha synuclein oligomer antibody validation, agreement title french : StressMarq biosciences - alpha synuclein oligomer antibody validation, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-06-14, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada